



Turkish Society of Gynecologic Oncology (TRSGO)

October 28, 2020 Cet Time 6.00-8.00 pm

Ovarian Cancer Consensus Meeting, Section II

High Grade Serous Ovarian Cancer, Genetic Assessment

Chairmen: Fuat Demirkıran, Orhan Ünal

Genetic assessment and counselling in ovarian cancer:
BRCA1/2 and non-BRCA1/2 mutation

Douglas Levine

BRCA1/2 and non-BRCA1/2 mutation would be considered a
helpful biomarker in treatment?

Douglas Levine

Clinical characteristics and management differences in
patient with BRCA1/2 mutation

Salih Taşkın

Risk reducing surgery based on germ-line mutation in gynecology

M. Faruk Köse

PARP inhibitors in first line therapy

Hande Turna



Follow the live webinar at www.surgical.tv

Free & easy registration with name-surname and e-mail address required.
Attend interactively; share your questions and comments live